The present invention provides methods dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment the invention relates to a method for treating a CNS disorder in a human which method comprises administering to the human in a fasted state a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder wherein the area under the serum concentration versus time curve (...

The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms deep vein thrombosis and acute coronary syndrome with said dosage form.

The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms deep vein thrombosis and acute coronary syndrome with said dosage form.

Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

The present invention provides methods dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment the invention relates to a method for treating a CNS disorder in a human which method comprises administering to the human in a fasted state a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder wherein the area under the serum concentration versus time curve (...

The present invention relates to a class of substituted 124-triazoles of formula (I) with activity as oxytocin antagonists uses thereof processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction particularly premature ejaculation (P.E.).

Methods and compositions for treating humans suffering from or preventing a human from suffering a physiological or psychiatric disease disorder or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine and more preferably optically pure (SS) enantiomer of reboxetine. The methods generall...

USO DE MALATO DE SUNITINIB NA PREPARAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE CáNCER. A invenção fornece usos de um composto de fórmula (1) ou um sal farmaceuticamente aceitável desse particularmente um sal de malato em combinação com vários agentes terapêuticos adicionais na preparação de medicamentos para o tratamento de câncer. A invenção também fornece regimes de dosagem terapêutica que usam o composto de fórmula (1) e um agente terapêutico adicional.

Forming amorphous atorvastatin comprises the steps of dissolving atorvastatin in a hydroxylic solvent followed by rapidly evaporating the solvent. In another aspect a composition comprises particles of amorphous atorvastatin and a core.